ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

08 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 

07 8 2024 16:02:54 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

31 7 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

01 7 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

20 6 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

23 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

13 5 2024 16:47:42 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

13 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

06 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

26 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Q2 Investor Conference Participation

09 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

14 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

12 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

05 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

28 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

16 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

16 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 1 2024 16:15:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 16:05:00 提供 Nasdaq GlobeNewswire